210 related articles for article (PubMed ID: 28436164)
21. Synthetic Analogs of Curcumin Modulate the Function of Multidrug Resistance-Linked ATP-Binding Cassette Transporter ABCG2.
Murakami M; Ohnuma S; Fukuda M; Chufan EE; Kudoh K; Kanehara K; Sugisawa N; Ishida M; Naitoh T; Shibata H; Iwabuchi Y; Ambudkar SV; Unno M
Drug Metab Dispos; 2017 Nov; 45(11):1166-1177. PubMed ID: 28904007
[TBL] [Abstract][Full Text] [Related]
22. Biophysical characterization of MDR breast cancer cell lines reveals the cytoplasm is critical in determining drug sensitivity.
Coley HM; Labeed FH; Thomas H; Hughes MP
Biochim Biophys Acta; 2007 Apr; 1770(4):601-8. PubMed ID: 17270349
[TBL] [Abstract][Full Text] [Related]
23. Effect of abemaciclib (LY2835219) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.
Wu T; Chen Z; To KKW; Fang X; Wang F; Cheng B; Fu L
Biochem Pharmacol; 2017 Jan; 124():29-42. PubMed ID: 27816545
[TBL] [Abstract][Full Text] [Related]
24. Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells.
Robey RW; Medina-Pérez WY; Nishiyama K; Lahusen T; Miyake K; Litman T; Senderowicz AM; Ross DD; Bates SE
Clin Cancer Res; 2001 Jan; 7(1):145-52. PubMed ID: 11205902
[TBL] [Abstract][Full Text] [Related]
25. Arylamino Esters As P-Glycoprotein Modulators: SAR Studies to Establish Requirements for Potency and Selectivity.
Teodori E; Dei S; Floriddia E; Perrone MG; Manetti D; Romanelli MN; Contino M; Colabufo NA
ChemMedChem; 2015 Aug; 10(8):1339-43. PubMed ID: 26012726
[TBL] [Abstract][Full Text] [Related]
26. Amine linked flavonoid dimers as modulators for P-glycoprotein-based multidrug resistance: structure-activity relationship and mechanism of modulation.
Chan KF; Wong IL; Kan JW; Yan CS; Chow LM; Chan TH
J Med Chem; 2012 Mar; 55(5):1999-2014. PubMed ID: 22320402
[TBL] [Abstract][Full Text] [Related]
27. Parguerenes: Marine red alga bromoditerpenes as inhibitors of P-glycoprotein (ABCB1) in multidrug resistant human cancer cells.
Huang XC; Sun YL; Salim AA; Chen ZS; Capon RJ
Biochem Pharmacol; 2013 May; 85(9):1257-68. PubMed ID: 23415901
[TBL] [Abstract][Full Text] [Related]
28. Aurones as modulators of ABCG2 and ABCB1: synthesis and structure-activity relationships.
Sim HM; Loh KY; Yeo WK; Lee CY; Go ML
ChemMedChem; 2011 Apr; 6(4):713-24. PubMed ID: 21302361
[TBL] [Abstract][Full Text] [Related]
29. Antitumor agents. 280. Multidrug resistance-selective desmosdumotin B analogues.
Nakagawa-Goto K; Chang PC; Lai CY; Hung HY; Chen TH; Wu PC; Zhu H; Sedykh A; Bastow KF; Lee KH
J Med Chem; 2010 Sep; 53(18):6699-705. PubMed ID: 20735140
[TBL] [Abstract][Full Text] [Related]
30. Tangeretin, a citrus pentamethoxyflavone, antagonizes ABCB1-mediated multidrug resistance by inhibiting its transport function.
Feng SL; Yuan ZW; Yao XJ; Ma WZ; Liu L; Liu ZQ; Xie Y
Pharmacol Res; 2016 Aug; 110():193-204. PubMed ID: 27058921
[TBL] [Abstract][Full Text] [Related]
31. Elacridar enhances the cytotoxic effects of sunitinib and prevents multidrug resistance in renal carcinoma cells.
Sato H; Siddig S; Uzu M; Suzuki S; Nomura Y; Kashiba T; Gushimiyagi K; Sekine Y; Uehara T; Arano Y; Yamaura K; Ueno K
Eur J Pharmacol; 2015 Jan; 746():258-66. PubMed ID: 25455500
[TBL] [Abstract][Full Text] [Related]
32. Vatalanib sensitizes ABCB1 and ABCG2-overexpressing multidrug resistant colon cancer cells to chemotherapy under hypoxia.
To KK; Poon DC; Wei Y; Wang F; Lin G; Fu LW
Biochem Pharmacol; 2015 Sep; 97(1):27-37. PubMed ID: 26206183
[TBL] [Abstract][Full Text] [Related]
33. Flavonoids inhibit breast cancer resistance protein-mediated drug resistance: transporter specificity and structure-activity relationship.
Katayama K; Masuyama K; Yoshioka S; Hasegawa H; Mitsuhashi J; Sugimoto Y
Cancer Chemother Pharmacol; 2007 Nov; 60(6):789-97. PubMed ID: 17345086
[TBL] [Abstract][Full Text] [Related]
34. Lower antioxidative capacity of multidrug-resistant cancer cells confers collateral sensitivity to protoflavone derivatives.
Stanković T; Dankó B; Martins A; Dragoj M; Stojković S; Isaković A; Wang HC; Wu YC; Hunyadi A; Pešić M
Cancer Chemother Pharmacol; 2015 Sep; 76(3):555-65. PubMed ID: 26198315
[TBL] [Abstract][Full Text] [Related]
35. Ixabepilone, a novel microtubule-targeting agent for breast cancer, is a substrate for P-glycoprotein (P-gp/MDR1/ABCB1) but not breast cancer resistance protein (BCRP/ABCG2).
Shen H; Lee FY; Gan J
J Pharmacol Exp Ther; 2011 May; 337(2):423-32. PubMed ID: 21262849
[TBL] [Abstract][Full Text] [Related]
36. Dimethoxyaurones: Potent inhibitors of ABCG2 (breast cancer resistance protein).
Sim HM; Lee CY; Ee PL; Go ML
Eur J Pharm Sci; 2008 Nov; 35(4):293-306. PubMed ID: 18725288
[TBL] [Abstract][Full Text] [Related]
37. Synthesis and biological evaluation of flavones and benzoflavones as inhibitors of BCRP/ABCG2.
Juvale K; Stefan K; Wiese M
Eur J Med Chem; 2013 Sep; 67():115-26. PubMed ID: 23851114
[TBL] [Abstract][Full Text] [Related]
38. Pyrrolopyrimidine derivatives and purine analogs as novel activators of Multidrug Resistance-associated Protein 1 (MRP1, ABCC1).
Schmitt SM; Stefan K; Wiese M
Biochim Biophys Acta Biomembr; 2017 Jan; 1859(1):69-79. PubMed ID: 27810353
[TBL] [Abstract][Full Text] [Related]
39. Novel microtubule-targeting agents, pyrrolo-1,5-benzoxazepines, induce apoptosis in multi-drug-resistant cancer cells.
Nathwani SM; Butler S; Fayne D; McGovern NN; Sarkadi B; Meegan MJ; Lloyd DG; Campiani G; Lawler M; Williams DC; Zisterer DM
Cancer Chemother Pharmacol; 2010 Aug; 66(3):585-96. PubMed ID: 20020128
[TBL] [Abstract][Full Text] [Related]
40. Computational classification models for predicting the interaction of drugs with P-glycoprotein and breast cancer resistance protein.
Erić S; Kalinić M; Ilić K; Zloh M
SAR QSAR Environ Res; 2014; 25(12):939-66. PubMed ID: 25435255
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
